References
- Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, et al. Trastuzaumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 2012;367:1783–91.
- Remillard S, Rebhun LI, Howie GA, Kupchan SM. Antimitotic activity of the potent tumor inhibitor maytansine. Science 1975;189:1002–5.
- Cassady JM, Chan KK, Floss HG. Recent developments in the maytansinoid antitumor agents. Chem Pharm Bull 2004; 52:1–26.
- Widdison WC, Wilhelm SD, Cavanagh EE, Whiteman KR, Leece BA, Kovtun Y, et al. Semisynthetic maytansine analogues for the targeted treatment of cancer. J Med Chem 2006;49:4392–408.
- Burris HA 3rd, Rugo HS, Vukelja SJ, Vogel CL, Borson RA, Limentani S, et al. Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. J Clin Oncol 2011;29:398–405.
- Carlson JA, Nooruddin Z, Rusthoven C, Elias A, Borges VF, Diamond JR, et al. Trastuzumab emtansine and stereotactic radiosurgery: An unexpected increase in clinically significant brain edema. Neuro Oncol Epub2014 Feb 3.
- DeAngelis L, Posner J. Neurologic complications of cancer (Contemporary Neurology Series). Vol. 73. 2nd ed. New York: Oxford University Press; 2009.
- Gabos Z, Sinha R, Hanson J, Chauhan N, Hugh J, Mackey JR, et al. Prognostic significance of human epidermal growth factor receptor positivity for the development of brain metastasis after newly diagnosed breast cancer. J Clin Oncol 2006;24:5658–63.
- Pestalozzi BC, Zahrieh D, Price KN, Holmberg SB, Lindtner J, Collins J, et al. Identifying breast cancer patients at risk for central nervous system (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG). Ann Oncol 2006;17:935–44.
- Chang J, Clark GM, Allred DC, Mohsin S, Chamness G, Elledge RM. Survival of patients with metastatic breast carcinoma: Importance of prognostic markers of the primary tumor. Cancer 2003;97:545–53.
- Kallioniemi OP, Holli K, Visakorpi T, Koivula T, Helin HH, Isola JJ. Association of c-erbB-2 protein over-expression with high rate of cell proliferation, increased risk of visceral metastasis and poor long-term survival in breast cancer. Int J Cancer 1991;49:650–5.
- Genentech. (2013) Direct healthcare professional communication of cases of severe hemorrhage reported with Kadcyla® (ado-trastuzumab emtansine). [cited 2014 Mar 12].Available from: http://www.gene.com/download/pdf/Kadcyla_DHCP%20letter.pdf.
- Beeram M, Krop IE, Burris HA, Girish SR, Yu W, Lu MW, et al. A phase 1 study of weekly dosing of trastuzumab emtansine (T-DM1) in patients with advanced human epidermal growth factor 2-positive breast cancer. Cancer 2012;118:5733–40.